Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Depreciation & Amortization (CF) (2017 - 2025)

Historic Depreciation & Amortization (CF) for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to $54000.0.

  • Vistagen Therapeutics' Depreciation & Amortization (CF) rose 3846.15% to $54000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $187000.0, marking a year-over-year increase of 3076.92%. This contributed to the annual value of $150000.0 for FY2025, which is 1811.02% up from last year.
  • Per Vistagen Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $54000.0 for Q4 2025, which was up 3846.15% from $53000.0 recorded in Q3 2025.
  • Over the past 5 years, Vistagen Therapeutics' Depreciation & Amortization (CF) peaked at $54000.0 during Q4 2025, and registered a low of $30600.0 during Q4 2022.
  • Its 5-year average for Depreciation & Amortization (CF) is $37326.3, with a median of $34500.0 in 2021.
  • In the last 5 years, Vistagen Therapeutics' Depreciation & Amortization (CF) skyrocketed by 6553.03% in 2021 and then tumbled by 2997.71% in 2022.
  • Vistagen Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $43700.0 in 2021, then fell by 29.98% to $30600.0 in 2022, then grew by 1.31% to $31000.0 in 2023, then increased by 25.81% to $39000.0 in 2024, then soared by 38.46% to $54000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $54000.0 for Q4 2025, versus $53000.0 for Q3 2025 and $40000.0 for Q2 2025.